恒瑞医药（600276）(01276)发布公告，关于回购公司A股股份的进展：2025年11月，公司通过上海证券 交易所交易系统以集中竞价交易方式回购股份97.99万股，已回购股份占公司总股本的比例为0.015%， 购买的最高价为人民币63.28元/股，最低价为人民币59.32元/股，已支付的总金额为人民币5978.85万元 (不含交易费用)。截至2025年11月30日，公司本次股份回购方案累计通过上海证券交易所交易系统以集 中竞价交易方式回购股份889.87万股，已回购股份占公司总股本的比例为0.13%，购买的最高价为人民 币70.00元/股，最低价为人民币59.32元/股，已支付的总金额为人民币5.95亿元(不含交易费用)。 ...

Core Viewpoint - Heng Rui Medicine (01276) has announced the progress of its A-share repurchase plan, indicating a strategic move to enhance shareholder value through share buybacks [1] Group 1: Share Repurchase Details - In November 2025, the company repurchased 979,900 shares through the Shanghai Stock Exchange, accounting for 0.015% of the total share capital, with a maximum purchase price of RMB 63.28 per share and a minimum of RMB 59.32 per share, totaling RMB 59.7885 million (excluding transaction fees) [1] - As of November 30, 2025, the cumulative repurchase amounted to 8,898,700 shares, representing 0.13% of the total share capital, with a maximum price of RMB 70.00 per share and a minimum of RMB 59.32 per share, totaling RMB 595 million (excluding transaction fees) [1]

Core Viewpoint - Heng Rui Medicine (01276) has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of injectable toremifene, indicating progress in its product pipeline [1] Group 1: Product Development - The injectable toremifene has been approved for indications including sedation and anesthesia during non-tracheal intubation surgeries and for induction and maintenance of general anesthesia [1] - The application for market approval is based on two key studies focused on sedation for mechanically ventilated patients in the Intensive Care Unit (ICU) [1] Group 2: Clinical Research - The HR7056-302 study is a Phase III clinical trial evaluating toremifene compared to standard first-line treatments for short-term sedation during critical care, involving 214 patients across 43 centers, led by Professor Guan Xiangdong from Sun Yat-sen University First Affiliated Hospital [1] - The HR7056-206 study is a multi-center Phase II clinical trial assessing toremifene for long-term sedation in critical care, with 24 patients enrolled from 18 centers, led by Professor Shen Feng from Guizhou Medical University Affiliated Hospital [1] - Both studies achieved their primary endpoints as expected [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has announced a share repurchase plan, indicating a strategic move to enhance shareholder value through buybacks [1] Summary by Categories Share Repurchase Details - As of November 30, 2025, the company has repurchased a total of 8.8987 million shares, which represents 0.13% of the total share capital [1] - The highest purchase price was RMB 70.00 per share, while the lowest was RMB 59.32 per share [1] - The total amount paid for the repurchased shares is RMB 595.2163 million, excluding transaction fees [1]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received the acceptance notice from the National Medical Products Administration for its drug application of injectable remimazolam tosylate, indicating progress in the drug approval process [1] Group 1: Drug Information - Drug Name: Injectable Remimazolam Tosylate [1] - Dosage Form: Injectable [1] - Acceptance Number: CXHS2500146 [1] - Application Stage: Market Approval [1] - Applicant: Jiangsu Hengrui Medicine Co., Ltd. [1] - Proposed Indication: Sedation during mechanical ventilation in intensive care [1]

Core Points - The launch of the China Drug Price Registration System aims to facilitate the globalization of Chinese innovative drugs and attract high-quality foreign drugs to the Chinese market, benefiting patients in China [1][4] - The system operates under a "one location acceptance, nationwide sharing, global openness" service mechanism, allowing pharmaceutical companies to independently declare and register drug prices [1][4] - The establishment of this system fills a gap in the national-level drug pricing disclosure framework in China, enhancing the credibility of registered prices compared to provincial systems [5] Group 1: System Overview - The China Drug Price Registration System (China Drug Registration) was officially launched on December 2, providing a platform for drug price registration and inquiry [1] - The system is a collaboration between the National Healthcare Security Administration and the Beijing Municipal Government, operated by a state-owned enterprise under a socialized operation model [1][4] - The registration process allows drug market authorization holders to voluntarily declare prices and is open for public inquiry, ensuring transparency [5] Group 2: Industry Impact - The system is expected to significantly impact the high-quality development of the pharmaceutical industry in China, aligning with the country's goal of building a healthy China and supporting the development of innovative drugs and medical devices [3][4] - By providing a platform for global price registration, the system helps Chinese pharmaceutical companies establish a comprehensive global pricing framework, enhancing the modernization of drug price governance [4][5] - The system's independent operation from provincial procurement platforms allows for a clearer distinction between market prices and negotiated prices under healthcare insurance [4][5]

证券之星消息，12月2日，医疗健康R（480016）指数报收于7315.52点，跌1.46%，成交161.03亿元，换 手率0.53%。当日该指数成份股中，上涨的有4家，济川药业以1.0%的涨幅领涨，下跌的有46家，泰格医 药以3.88%的跌幅领跌。 医疗健康R（480016）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sh603259 | 药明康德 | 13.66% | 89.42 | -3.12% | 2668.08 | 医药生物 | | sh600276 | 恒瑞医药 | 11.00% | 61.12 | -1.32% | 4056.66 | 医药生物 | | sz300760 | 迈瑞医疗 | 7.57% | 200.62 | -0.50% | 2432.40 | 医药生物 | | sh688271 | 联影医疗 | 4.27% | 128.71 | -1.97% | 1060.77 | 医药生物 | | sh600436 | 片 ...

Core Viewpoint - Heng Rui Medicine has received acceptance for its drug application for injectable remimazolam tosylate from the National Medical Products Administration, indicating progress in its development for sedation during mechanical ventilation in intensive care settings [1] Group 1 - The drug's approved indications include sedation and anesthesia for non-intubated surgeries and procedures, as well as induction and maintenance of general anesthesia [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received the acceptance notice from the National Medical Products Administration for its drug application of injectable tofenamic acid remimazolam, indicating progress in its drug development pipeline [1] Group 1: Drug Information - Tofenic acid remimazolam is a benzodiazepine drug and a short-acting GABAa receptor agonist, which produces sedative and anesthetic effects by inhibiting neuronal activity [1] - The advantages of tofenamic acid remimazolam include rapid onset, short recovery time, and minimal impact on respiratory and cardiovascular systems [1] Group 2: Market Context - The drug was developed by PAION AG and has been approved in Japan in January 2020, in the United States in October 2020, and in China in July 2020 [1] - The global sales of remimazolam are projected to reach approximately $59.22 million in 2024 [1] Group 3: R&D Investment - The cumulative research and development investment for injectable tofenamic acid remimazolam has reached approximately 184 million yuan [1]

Core Viewpoint - Heng Rui Medicine has received acceptance notification from the National Medical Products Administration for its drug application of injectable remimazolam tosylate, indicating progress in its market entry [1] Group 1: Product Information - Remimazolam tosylate is a short-acting GABAa receptor agonist belonging to the benzodiazepine class, which produces sedative and anesthetic effects by inhibiting neuronal activity [1] - The advantages of remimazolam tosylate include rapid onset, short recovery time, and minimal impact on respiratory and cardiovascular systems [1] Group 2: Market Context - The drug was developed by PAION AG and has been approved for sale in Japan, the United States, and China in 2020 [1] - The global sales for remimazolam tosylate are projected to reach approximately $59.22 million in 2024 [1] Group 3: R&D Investment - The cumulative research and development investment for injectable remimazolam tosylate has reached approximately 184 million yuan [1]